Gladskin contains billions of bacteria, of which the vast majority protects our skin. To maintain a healthy skin environment, it is necessary to maintain a good bacterial balance. The disruption of this balance can result in, or aggravate, skin conditions. Traditional skin products and antibiotics do not differentiate between good and bad bacteria, and therefore also remove the beneficial bacteria that protect us. Gladskin contains Staphefekt.

Engages in the development of clinically differentiated drug for dermatology

Fleming & Co. Pharmaceuticals develops and manufactures prescription and over the counter therapies. It develops products for clinical conditions in allergy, pediatrics, nephrology, nutrition, and obstetrics and gynecology. The company was founded by Tommye Fleming on August 9, 1960 and is headquartered in Jefferson City, MO

Advitech Inc. is a health sciences and technology company, which develops, manufactures and marketes proprietary natural ingredients and formulations for oral and topical applications. Its products are based on three technological platforms: a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, XP-828L for immune mediated inflammatory disorders and IM for anti-aging and wound healing. Advitech was founded in 1997 and is headquartered in Québec, Canada

Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France.

Takata Seiyaku Co. Ltd. manufactures and sales pharmaceutical products. It also manufactures beverages and health foods. The company was founded in 1895 and is located in Tokyo, Japan

New Century Pharmaceuticals, Inc. is a biopharmaceutical company with an Oncology and Anti-infective focus which uses leading expertise.

Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Xuzhou Changnan Medical Technology Co., Ltd., established on 2016-12-06, Business scope includes medical device technology development,Sales;Computer software and hardware development,Sales;Medical Information Consulting Service;Conference Services;Enterprise Marketing Planning;hardware products,daily necessities,Office Supplies,Cleaning Products,cosmetic,sporting goods,electronic product,Instrument sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Chengdu Xingbeijia Biotechnology Co., Ltd., established on 2016-10-08, Business scope includes biological research and experimental development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. It operates through the following segments: Branded Pharmaceuticals, Contract Manufacturing, Obesity and Weight Management, Europe, and Specialty Products. The Branded Pharmaceuticals segment involves the sale of branded pharmaceutical products. The Contract Manufacturing segment involves the contract manufacturing of pharmaceutical, food and animal nutrition products on behalf of domestic and international pharmaceutical and food companies. The Obesity and Weight Management segment is involved in the manufacture and sale of a range of products across a number of channels including FMCG, pharmacy, health food stores and online. The Europe segment is involved in the manufacture and sale of products within Europe. The Specialty Products segment involves in the sale of human and animal nutrition products, incorporating the sale of ingredients and additives for use in the pharmaceutical and food industries. The company was founded in 1997 and is headquartered in Melbourne, Australia.

Johnson & Johnson (China) Co., Ltd., established on 1992-01-20, Business scope includes licensed projects:food business,Import and export,Cosmetic production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Manufacture of health care consumer products and cosmetics,including baby health care products,Feminine Hygiene Products,Oral hygiene products,Adult hair and skin care products, etc.;Production of baby laundry detergent,Sell ​​self-produced products;The above products and similar products and beauty and skin care equipment,disinfection products,Wholesale of Class II Medical Devices,Sales,commission agent(except auction),in baby care,Product research and development in areas such as adult care,Transfer of R&D results,Technical support and technical services related to the transfer of R&D results;Carry out the following business activities with other companies invested by Johnson & Johnson in Shanghai;Sublease of premises and workshops,shared facilities and resources.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere currently has a number of product candidates in its pipeline at varying stages. There are multiple product candidates in clinical development as well as several pre-clinical development/research programs. The Company considers specific criteria when deciding whether to devote resources to a development program. The markets that Emisphere seeks to enter for a potential product should be substantial. The product candidate should meet a clear unmet medical or market need and the product profile should clearly differentiate Emisphere's products. The Company also considers the level of product development effort in relation to a reasonable return on investment within an acceptable timeframe.

Xi'an Jiaotong University Science and Technology Park Boyuan Biomedicine Co., Ltd., established on 2003-08-28, Business scope includes pharmaceuticals,Research and Development of Medical Devices,Sales of Medical Devices(The license is valid until2008year12moon17day).

The Institute for Biomathematics and Biometry conducts fundamental research in areas including Epidemiology, Analysis of Complex Experimental Data, Analysis of Environmental Chemicals, Machine Learning, Bacterial Communication Processes in the Rhizosphere, the Regulation Pathway of NF-κB and Coagulation Cascades.

Part of Bayer AG, Bayer Yakuhin Ltd. is a company headquartered in Osaka, Japan. The firm manufactures pharmaceuticals and diagnostic substances.

Stiefel, a [GSK](/organization/glaxosmithkline) company, works to advance dermatology and skin science around the world. The company’s deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel’s most valuable asset is its global network of nearly 3,500 driven associates. By combining expertise, knowledge and imagination, Stiefel delivers exceptional ethical, over-the-counter and aesthetic products to its customers in more than 100 countries around the world, ultimately providing a unique Stiefel skin health experience. Stiefel is also committed to improving today’s treatments and exploring tomorrow’s innovations. Each year, the company invests more than $100 million in developing the most advanced skin health solutions.